Literature DB >> 2390421

Screening for aminoglycoside auditory toxicity in the old.

R Cheung1, P Clark, P W Nicholson, A A Deshmukh, C J O'Neill, S M Dobbs, R J Dobbs.   

Abstract

1. We have investigated 22 patients receiving gentamicin, mean (s.d.) age 78 (6) years for auditory toxicity, using a standard audiometric technique in a sound-treated room (Study 1). 2. Use of a portable audiometer might allow a larger and more representative proportion of patients treated with aminoglycosides to be screened for ototoxicity. A method for detecting high frequency loss suitable for use in the ward was evaluated in 12 volunteers aged 27 (4) years (Study 2). 3. The error inherent in taking hearing at the start of treatment as a reference point was measured in 16 patients, aged 81 (8) years, prescribed non-ototoxic antibacterials (Study 3). 4. A significant (P = 0.05) reduction in hearing threshold was detected in Study 1, although psychometric tests revealed unchanged or improved ability to co-operate. This occurred only at 4000 Hz, the highest frequency used. The magnitude of this loss, mean 2.5 dB, was similar to that of the improvement in threshold detected (P = 0.0004) early in the course of treatment in Study 3. Thus, underestimation of ototoxicity is likely. 5. If a change of threshold of 10 dB or more is taken arbitrarily to represent a real change in hearing, then there was a significant excess of patients in Study 1 with losses at 4000 Hz only (P = 0.032). The six with such losses at this frequency were older than the rest. However, there was a significant (P less than 0.02) positive correlation between log mean predose serum gentamicin concentration and age. Thus, it remains to be determined whether presbyacusis sensitizes those hair cells which it does not destroy to toxic damage. 6. The cumulative dose of gentamicin (for a course of the duration given) was calculated according to published prescribing aids. There was no systematic reduction in the ratio of the dose recommended by a given aid to the dose prescribed in the six with hearing losses as defined above. 7. In Study 2, thresholds obtained at 6000 Hz in the open ward were, on average, 0.9 dB higher than in the sound treated room, but the effect of venue did not reach statistical significance. In the morning thresholds were marginally, but significantly (P = 0.04), lower than in the afternoon. Precision, as measured by the standard deviation of replicate determination, was independent of test conditions. Using multiple (ten) threshold determinations appeared to improve resolution.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2390421      PMCID: PMC1368269          DOI: 10.1111/j.1365-2125.1990.tb03737.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Cochlear damage resulting from kanamycin and furosemide.

Authors:  R E Brummett; J Traynor; R Brown; D Himes
Journal:  Acta Otolaryngol       Date:  1975 Jul-Aug       Impact factor: 1.494

2.  Effect of heparin on gentamicin concentration in blood.

Authors:  E Yourassowsky; M E DeBroe; R J Wieme
Journal:  Clin Chim Acta       Date:  1972-11       Impact factor: 3.786

3.  Correlation of serum creatinine concentration and gentamicin half-life.

Authors:  R E Cutler; A M Gyselynck; W P Fleet; A W Forrey
Journal:  JAMA       Date:  1972-02-21       Impact factor: 56.272

4.  A prospective study of gentamicin ototoxicity.

Authors:  O Winkel; M M Hansen; K Kaaber; K Rozarth
Journal:  Acta Otolaryngol       Date:  1978 Sep-Oct       Impact factor: 1.494

5.  OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics.

Authors:  A W Kelman; B Whiting; S M Bryson
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

6.  Gentamicin therapy in renal failure: a nomogram for dosage.

Authors:  R A Chan; E J Benner; P D Hoeprich
Journal:  Ann Intern Med       Date:  1972-05       Impact factor: 25.391

7.  Gentamicin dosages for renal insufficiency. Adjustments based on endogenous creatinine clearance and serum creatinine concentration.

Authors:  M C McHenry; T L Gavan; R W Gifford; N A Geurkink; R A Van Ommen; M A Town; J G Wagner
Journal:  Ann Intern Med       Date:  1971-02       Impact factor: 25.391

Review 8.  Why monitor serum levels of gentamicin?

Authors:  M Barza; M Lauermann
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

9.  Histopathological findings in clinical gentamicin ototoxicity.

Authors:  M Keene; M Hawke; H O Barber; J Farkashidy
Journal:  Arch Otolaryngol       Date:  1982-02

10.  A controlled study of the reliability of pure tone audiometry for the detection of gentamicin auditory toxicity.

Authors:  P G Davey; F J Jabeen; E S Harpur; P M Shenoi; A M Geddes
Journal:  J Laryngol Otol       Date:  1983-01       Impact factor: 1.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.